NeurAxis, Inc. (NASDAQ:NRXS – Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.64 and traded as low as $6.59. NeurAxis shares last traded at $6.60, with a volume of 125,711 shares.
Wall Street Analyst Weigh In
Separately, Zacks Research raised shares of NeurAxis to a “hold” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.
Read Our Latest Research Report on NRXS
NeurAxis Stock Performance
The stock has a market capitalization of $82.88 million, a price-to-earnings ratio of -3.59 and a beta of 1.38. The business has a 50-day moving average of $6.84 and a 200-day moving average of $6.64.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of NRXS. AIGH Capital Management LLC acquired a new position in shares of NeurAxis in the 2nd quarter worth approximately $3,801,000. Panoramic Capital LLC purchased a new position in shares of NeurAxis during the 2nd quarter worth approximately $841,000. Renaissance Technologies LLC purchased a new position in shares of NeurAxis during the 1st quarter worth approximately $569,000. BlackRock Inc. purchased a new position in shares of NeurAxis during the 2nd quarter worth approximately $429,000. Finally, T3 Companies LLC acquired a new stake in NeurAxis in the 3rd quarter valued at approximately $200,000. Hedge funds and other institutional investors own 11.77% of the company’s stock.
NeurAxis Company Profile
NeurAxis, Inc (NASDAQ: NRXS) is a medical technology company focused on developing and commercializing non-invasive neuromodulation therapies for functional gastrointestinal and other nervous-system-related disorders. The company’s approach is designed to influence neural signaling through targeted electrical stimulation.
NeurAxis’s principal product is IB-Stim, a prescription, percutaneous electrical nerve-field stimulation device intended for use in adolescents with functional abdominal pain associated with irritable bowel syndrome and related functional gastrointestinal disorders.
Further Reading
- Five stocks we like better than NeurAxis
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
